TG Therapeutics announced updated clinical data from its Phase I/Ib trial of ublituximab, the company’s novel glycoengineered anti-CD20 monoclonal antibody in combination with umbralisib, the company’s oral, next generation PI3K delta inhibitor, and bendamustine, in patients with Diffuse Large B-cell Lymphoma, or DLBCL, and Follicular Lymphoma, or FL. Data from this trial was presented yesterday evening during a poster session at the American Society of Hematology, or ASH. This poster presentation includes data from patients with relapsed or refractory DLBCL or FL treated with the triple combination of umbralisib, ublituximab and bendamustine. Thirty-nine patients were evaluable for safety of which 38 were evaluable for efficacy. Twenty-two patients were refractory to prior treatment. Overall, the triple combination was well tolerated and highly active in patients with advanced indolent and aggressive NHL, including those not eligible for HD/SCT or CD19 CART therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.